Q3 2023 Results
Company overview
Innovation: Pipeline overview
Financial review
Financial performance
Novartis pipeline in Phase 3
Oncology
Code
Name
Solid tumors
Mechanism
Indication(s)
AAA617
Conclusions
PluvictoⓇ
Radioligand therapy target PSMA
Metastatic castration-resistant prostate cancer (mCRPC),
pre-taxane
AAA6011
LutatheraⓇ
Radioligand therapy target SSTR
KRAS inhibitor
Metastatic hormone sensitive prostate cancer (mHSPC)
Gastroenteropancreatic neuroendocrine tumors, 1st line in G2/3
tumors (GEP-NET 1L G3)
2/3L Non-small cell lung cancer
JDQ443 opnurasib
Hematology
ABL001 ScemblixⓇ
ETB115 Promacta®
LNP023 iptacopan
MBG453
VAY736
BCR-ABL inhibitor
Thrombopoietin receptor
(TPO-R) agonist
CFB inhibitor
sabatolimab
ianalumab
TIM3 antagonist
BAFF-R inhibitor
Chronic myeloid leukemia, 1st line
Radiation sickness syndrome
Atypical hemolytic uraemic syndrome
Myelodysplastic syndrome
1L Immune Thrombocytopenia
2L Immune Thrombocytopenia
warm Autoimmune Hemolytic Anemia
Appendix
Innovation: Clinical trials
Cardiovascular
References
Abbreviations
INNOVATION
8 lead indications
Lead indication
Code
EXV811 atrasentan
FUB523 zigakibart
KJX839 Leqvio®
Name
Mechanism
ETA receptor antagonist
Anti-APRIL
siRNA (regulation of LDL-C)
LNP023 iptacopan
CFB inhibitor
TQJ230
pelacarsen
ASO targeting Lp(a)
Indication(s)
IgA nephropathy
IgA nephropathy
CVRR-LDLC
Primary prevention
Hyperlipidemia, pediatrics
IgA nephropathy
C3 glomerulopathy
C3 glomerulopathy, pediatrics
IC-MPGN
Secondary prevention of cardiovascular events in patients
with elevated levels of lipoprotein (a) (CVRR-Lp(a))
Immunology
Neuroscience
Code
Name
AMG334 AimovigⓇ
BAF312 MayzentⓇ
LOU064 remibrutinib
OAV101 AVXS-101
OMB157 KesimptaⓇ
Mechanism
CGRPR antagonist
S1P1,5 receptor modulator
BTK inhibitor
SMN1 gene replacement therapy
CD20 Antagonist
Indication(s)
Migraine, pediatrics
Multiple sclerosis, pediatrics
Multiple sclerosis
SMA IT administration
Multiple sclerosis, pediatrics
Code
AIN457
Name
Cosentyx®
Mechanism
IL17A inhibitor
IgE inhibitor
remibrutinib
IGE025 Xolair®
LOU064
QGE031 ligelizumab
VAY736 ianalumab
BTK inhibitor
IgE inhibitor
BAFF-R inhibitor
Indication(s)
Giant cell arteritis:
Polymyalgia rheumatica
Rotator cuff tendinopathy
Food allergy
Chronic spontaneous urticaria
Chronic spontaneous urticaria, pediatrics
CINDU
Food allergy
Sjögren's
Lupus Nephritis
Systemic lupus erythematosus
1. 177 Lu-dotatate in US.
36 Investor Relations | Q3 2023 Results
Others
Code
IB&GH
Name
Mechanism
COA566 Coartem®
PGH-1 (artemisinin
combination therapy)
Others
RTH258 BeovuⓇ
VEGF Inhibitor
Indication(s)
Malaria, uncomplicated (<5kg patients)
Diabetic retinopathy
NOVARTIS | Reimagining MedicineView entire presentation